© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Geoffrey R. Oxnard, MD | Authors
Articles
Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC
April 30, 2010
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC).